The European Fund for Regional Development (ERDF) has awarded a subsidy to Liposoma Health in 2022. With the help of this grant, Liposoma Health has been given the opportunity to develop very small liposomes, the Small Unilamellar Vesicles (SUV).
Several scientific studies have shown that liposomes have an extensive palette of diverse molecular applications, the main application at present being the improved delivery of various medicinal substances. Preliminary studies have shown that liposomes with a specifically tuned very small size, the Small Unilamellar Vesicles (SUV), have various positive health effects on multiple metabolic mechanisms. Liposoma Heath has developed an intravenous product in which the active substance is the SUV itself. SUVs consisting of phosphatidylcholine, a subclass of phospholipids that incorporate choline into their hydrophilic parent group, as such are not new, but the specific composition and dosing regimen are new. In this treatment known as lipid replacement therapy the SUVs function as cholesterol mobilizers. The development of the intravenous SUV is important because the current drugs (mostly statins) around cholesterol and other blood fats have many side effects and the usefulness of these drugs (weighing the pros and cons) is often up for debate. Contrary to currently available drugs, the SUV do not have a direct effect on physical (enzymatic) processes. This gives the SUVs the potential to be a good alternative to current standard-of-care, especially statins.
AMSTERDAM SCIENCE PARK & ALMERE
LIPOSOMA is a liposome and nanoparticle service company based in the Netherlands. LIPOSOMA distinguishes itself by providing both high standard R&D services and contract manufacturing. Our team consists of world leading scientists capable of engineering a wide range of liposomes and other lipid based nano particles, containing the most complex compounds. Our services are provided with state of the art equipment, in our laboratories at Science Park Amsterdam and our large scale production facility in Almere. Science Park is a vibrant melting pot where science, business and innovation meet. The park hosts the University of Amsterdam’s Faculty of Science, dozens of renowned research institutes and some 150 companies, from start-ups to multinationals. We are proud that LIPOSOMA is one of these companies, literally located at the interface of science and entrepreneurship.
LIPOSOMA IS A LEADER IN
LIPOSOME TECHNOLOGY BECAUSE
More than 40 years of experience in developing liposomal formulations and applications
Integrating knowledge of well known liposome academics into our liposome technology
Our customers include some of the most prominent academic & private research institutes worldwide